Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durability of Stavudine, Lamivudine and Nevirapine Among Advanced HIV-1 Infected Patients With/Without Prior Co-Administration of Rifampicin: A 144-Week Prospective Study

NCT00703898 is registered in ClinicalTrials.gov with Bamrasnaradura Infectious Diseases Institute as lead sponsor.

NCT NCT00703898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00703898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durability of Stavudine, Lamivudine and Nevirapine Among Advanced HIV-1 Infected Patients With/Without Prior Co-Administration of Rifampicin: A 144-Week Prospective Study
Lead sponsor
Bamrasnaradura Infectious Diseases Institute
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2004
Completion date
April 30, 2010
Enrollment
140 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections